Danielle Bucco

Fostamatinib resulted in clinically meaningful, ongoing platelet responses and a low rate of bleeding events in 43% of patients with chronic immune thrombocytopenic purpura with long-disease duration.

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.

Suresh A. Ramalingam, MD, discusses the exciting findings from the KEYNOTE-189 and IMpower150 immunotherapy trials in patients with non–small cell lung cancer.

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.

Ravi Salgia, MD, PhD, discusses the evolving role of ALK-directed therapies for patients with non-small cell lung cancer.

Brian T. Hill, MD, PhD, discusses acalabrutinib and ibrutinib’s efficacy in patients with mantle cell lymphoma and highlights emerging novel strategies in the treatment landscape.

Kerstin Junker, MD, PhD, discusses the need to identify prognostic biomarkers for patients with RCC.

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.

Mark E. Hatley, MD, discusses the research of endothelial progenitor cells in pediatric patients with rhabdomyosarcoma and how it can lead to thorough analyses of the tumor cells.

John Richter, MD, discusses the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.

Miguel Perales, MD, discusses the impact of the FDA approval of letermovir for patients with CMV prophylaxis following transplantation.

Matthew Kulke, MD, discusses the evolving treatment paradigm for patients with neuroendocrine tumors.

Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.

Sharad Ghamande, MD, discusses the findings from GOG/NRG-0265, as well as the impact of vaccines for patients with cervical cancer.

Arun S. Singh, MD, discusses the developing role of immunotherapy in patients with GISTs, particularly the randomized phase II trial investigating nivolumab as a single agent and in combination with ipilimumab.

Marc A. Bjurlin, DO, discusses ongoing efforts to optimize prostate cancer screening.

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.

Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.

Gabriel Mannis, MD, discusses novel therapies shifting the treatment paradigm for patients with AML.

Malcolm Mason, MD, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.

Jennifer Eads, MD, discusses the classification of NETs versus NECs in gastrointestinal cancer.

Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.

Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.